BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
29.45
+0.03 (+0.10%)
At close: 4:00PM EDT

29.45 0.00 (0.00%)
After hours: 5:08PM EDT

Stock chart is not supported by your current browser
Previous Close29.42
Open29.57
Bid29.45 x 300
Ask29.50 x 100
Day's Range29.20 - 29.68
52 Week Range24.54 - 29.93
Volume6,867,608
Avg. Volume7,688,454
Market Cap40.626B
Beta0.99
PE Ratio (TTM)387.50
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up
    Market Realist7 hours ago

    Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up

    On April 25, Thermo Fisher Scientific (TMO) announced its earnings results for 1Q18, which ended on March 31. Its revenues grew ~23% to ~$5.9 billion YoY (year-over-year). The sales results came in ahead of analysts’ estimate of ~$5.6 billion.

  • Boston Scientific Raised Its 2018 Outlook
    Market Realist10 hours ago

    Boston Scientific Raised Its 2018 Outlook

    On April 25, Boston Scientific announced its 1Q18 earnings results. Boston Scientific’s results exceeded analysts’ estimates and the company guidance. During the earnings release, Boston Scientific updated its outlook for fiscal 2018. The company expects to register fiscal 2018 sales of $9.75 billion–$9.9 billion. The EPS (earnings per share) in fiscal 2018 is expected to be $1.37–$1.41.

  • Boston Scientific’s 1Q18 Results: Key Highlights
    Market Realist10 hours ago

    Boston Scientific’s 1Q18 Results: Key Highlights

    Boston Scientific: Strong 1Q18 Results, Higher 2018 OutlookBoston Scientific announced its 1Q18 results

  • Thomson Reuters StreetEvents18 hours ago

    Edited Transcript of BSX earnings conference call or presentation 25-Apr-18 12:00pm GMT

    Q1 2018 Boston Scientific Corp Earnings Call

  • Boston Scientific Ducks 'Choppy' Earnings Season That Slammed Edwards
    Investor's Business Dailyyesterday

    Boston Scientific Ducks 'Choppy' Earnings Season That Slammed Edwards

    Boston Scientific rose Wednesday after quarterly sales and adjusted profit beat, but investors are still waiting for an update on its heart valves.

  • Reutersyesterday

    Heart valve demand helps drive Boston Scientific's forecast

    Boston Scientific Corp raised its full-year forecast on Wednesday after reporting stronger-than-expected growth across its businesses, soothing fears that it was losing share in the lucrative market for heart valves. The company, which lags behind Medtronic Plc and Edwards Lifesciences Corp in the heart valves market, is pinning its hopes on its updated Lotus device, set for launch in 2019, following the withdrawal of an earlier version from Europe last year.

  • Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View
    Zacksyesterday

    Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View

    Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.

  • Should Boston Scientific Corporation’s (NYSE:BSX) Recent Earnings Decline Worry You?
    Simply Wall St.yesterday

    Should Boston Scientific Corporation’s (NYSE:BSX) Recent Earnings Decline Worry You?

    For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...

  • Associated Pressyesterday

    Boston Scientific: 1Q Earnings Snapshot

    Boston Scientific Corp. (BSX) on Wednesday reported first-quarter net income of $298 million. On a per-share basis, the Marlborough, Massachusetts-based company said it had net income of 21 cents. Earnings, ...

  • Reutersyesterday

    Medical device maker Boston Scientific posts 10 pct rise in sales

    U.S. medical device maker Boston Scientific Corp reported a 10 percent rise in first-quarter net sales on Wednesday, helped by higher demand for its products, including pacemakers and heart valves. Net ...

  • Medical Product Stock Earnings Roster for Apr 25: LH & More
    Zacks2 days ago

    Medical Product Stock Earnings Roster for Apr 25: LH & More

    Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.

  • Will BSX’s 1Q18 Results Support Its Upward Trend?
    Market Realist2 days ago

    Will BSX’s 1Q18 Results Support Its Upward Trend?

    Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.

  • Will Boston Scientific Beat 1Q18 Earnings Estimates?
    Market Realist2 days ago

    Will Boston Scientific Beat 1Q18 Earnings Estimates?

    In 1Q18, Boston Scientific (BSX) is expected to report adjusted EPS (earnings per share) of $0.32, representing YoY (year-over-year) growth of ~8.7%. The company reported adjusted EPS of $0.34 in fiscal 4Q17, and it had registered YoY growth of ~14.8%. The adjusted EPS were in line with Wall Street expectations.

  • Boston Scientific’s 1Q18 Revenues: What to Expect
    Market Realist3 days ago

    Boston Scientific’s 1Q18 Revenues: What to Expect

    On April 25, Boston Scientific (BSX) plans to announce its 1Q18 earnings results—the quarter that ended on March 31. According to Wall Street analysts’ estimates, the company’s 1Q18 revenues are expected to come in at $2.34 billion, representing YoY (year-over-year) growth of ~8.4%.

  • Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings
    Market Realist3 days ago

    Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings

    The company has been growing aggressively through strategic acquisitions. This month, the company announced the acquisition of Nvision Medical Corporation in the area of women’s health and Securus Medical in the area of electrophysiology. The company is slated to announce its 1Q18 earnings results on April 25. In this article, let’s discuss the company’s Wall Street recommendations and target prices for the next 12 months.

  • Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
    Investor's Business Daily7 days ago

    Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves

    Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.

  • Boston Scientific buys Harker School grad's med-tech business for $275M
    American City Business Journals9 days ago

    Boston Scientific buys Harker School grad's med-tech business for $275M

    San Bruno-based nVision makes a microcatheter device used to screen for ovarian cancer and was founded by a 32-year-old female CEO who was honored last year as a distinguished alumnus of the Harker School in San Jose. She had raised only $17 million in venture funding before the sale.

  • Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?
    Zacks9 days ago

    Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?

    Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.

  • Boston Scientific buys nVision Medical for $275 million
    American City Business Journals9 days ago

    Boston Scientific buys nVision Medical for $275 million

    California-based nVision makes a microcatheter device used to screen for ovarian cancer.

  • Forbes10 days ago

    A 32-Year-Old's Startup, Inspired By A Health Scare, Sells For $275 Million

    Surbhi Sarna decided she wanted to start a woman's health company after she suffered from an ovarian cyst so painful she passed out at age 15. Now she is 32, and her company is being bought by Boston Scientific.

  • WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes
    Zacks14 days ago

    WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes

    The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.

  • Abbott’s Latest Valuation Metrics in April 2018
    Market Realist15 days ago

    Abbott’s Latest Valuation Metrics in April 2018

    On April 6, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings ratio) of 20.1x, while its PE was 57.6x. A lower forward estimate compared to the current PE represents analysts’ expectations that a company will generate higher earnings over the next 12 months.

  • Abbott’s Stock Price Momentum Continues: What’s Ahead?
    Market Realist16 days ago

    Abbott’s Stock Price Momentum Continues: What’s Ahead?

    On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.

  • See what the IHS Markit Score report has to say about Boston Scientific Corp.
    Markit16 days ago

    See what the IHS Markit Score report has to say about Boston Scientific Corp.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $15.80 billion.

  • Analysts’ Latest Recommendations and Target Prices for Abbott
    Market Realist16 days ago

    Analysts’ Latest Recommendations and Target Prices for Abbott

    Abbott Laboratories (ABT) showed an impressive performance in 2017 despite a challenging macroeconomic environment and big-ticket acquisitions. The company reported strong 2017 results on January 24, 2018, and it has secured a number of product approvals and reimbursement approvals since then, strengthening its market position.